Compare
BioCryst Pharmaceuticals Inc vs Repligen Corp vs Novavax Inc vs Halozyme Therapeutics, Inc.
| Latest fiscal year | BioCryst Pharmaceuticals Inc BCRX | Repligen Corp RGEN | Novavax Inc NVAX | Halozyme Therapeutics, Inc. HALO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $874.84M | $738.26M | $1.12B | $1.40B |
| Revenue growth (YoY) | +94.1% | +16.4% | +64.7% | +37.6% |
| Gross margin | n/a | 52.3% (computed) | 93.5% (computed) | 83.6% (computed) |
| Operating margin | 39.0% | 7.5% | 40.3% | 33.6% |
| Net margin | 30.2% | 6.6% | 39.2% | 22.7% |
| Net income | $263.86M | $48.89M | $440.30M | $316.89M |
| EPS (Diluted) | $1.21 | $0.86 | $2.58 | $2.56 |
| Operating cash flow | $347.37M | $117.42M | -$244.63M | $651.56M |
| Free cash flow | $344.90M | $93.90M | n/a | $644.59M |
| Cash & equivalents | $89.74M | $566.02M | $240.63M | $133.82M |
| Total assets | $514.16M | $2.95B | $1.18B | $2.53B |
| Total liabilities | $633.31M | $843.57M | $1.30B | $2.48B |
| Shareholders' equity | -$119.15M | $2.11B | -$127.75M | $48.81M |
| Return on year-end equity | n/a | 2.3% | n/a | 649.2% |
| Shares outstanding | 213.06M | 56.33M | 162.58M | 117.78M |
Revenue, most recent five fiscal years
| Fiscal year | BioCryst Pharmaceuticals Inc | Repligen Corp | Novavax Inc | Halozyme Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $874.84M Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $1.12B Ended 2025-12-31 | $1.40B Ended 2025-12-31 |
| 1 year earlier | $450.71M Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $682.16M Ended 2024-12-31 | $1.02B Ended 2024-12-31 |
| 2 years earlier | $331.41M Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $983.71M Ended 2023-12-31 | $829.25M Ended 2023-12-31 |
| 3 years earlier | $270.83M Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $1.98B Ended 2022-12-31 | $660.12M Ended 2022-12-31 |
| 4 years earlier | $157.17M Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $1.15B Ended 2021-12-31 | $443.31M Ended 2021-12-31 |